In this list, we will take a look at the 5 best beaten down stocks to invest in according to analysts. If you wish to see the full list, visit 10 Best Beaten Down Stocks to Invest in According to Analysts.

5. FitLife Brands, Inc. (NASDAQ:FTLF)

Price Target Upside: 97.07%

FitLife Brands, Inc. (NASDAQ:FTLF) is one of the best 52-week low stocks on our list.

TheFly reported on April 6 that Roth Capital reduced its price target on FTLF to $17 from $25 while maintaining a Buy rating after the company reported weaker-than-expected fourth-quarter results. The firm attributed the earnings decline to slowing demand in certain online product lines, elevated protein input costs, and the discontinuation of CBD-related offerings. It also noted that while select core products continue to perform well, other segments that began losing momentum in the third quarter extended their slowdown into the fourth quarter.

In addition to that, it was reported on April 1 that FitLife Brands, Inc. (NASDAQ:FTLF) reported fourth-quarter fiscal 2025 revenue of $25.9 million, compared with $15 million in the same period last year. Management noted that most brand groups delivered strong performance during 2025, except MRC, which saw a 15% revenue decline over the year. Excluding MRC and MusclePharm, legacy FitLife brands generated about 6% organic growth. MusclePharm also contributed with 5% organic growth across both online and wholesale channels. Additionally, Irwin, in its first full quarter under ownership, recorded 6% organic growth. Overall, the results reflected broad-based expansion across key segments despite weakness in one brand category.

FitLife Brands, Inc. (NASDAQ:FTLF) is a consumer health and wellness company that develops and markets nutritional supplements and lifestyle products. Its brands focus on fitness, weight management, and active living.

4. Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Price Target Upside: 109.46%

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the best 52-week low stocks on our list.

TheFly reported on April 13 that Evercore ISI reduced its price target on VRDN to $24 from $32 while maintaining an Outperform rating ahead of the company’s first-quarter earnings update. The adjustment reflects a revised outlook incorporated into the firm’s preview of upcoming results.

In other news, it was reported earlier on April 6 that Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) declined sharply after Amgen reported positive Phase 3 results for Tepezza delivered via subcutaneous injection using an on-body device in patients with moderate to severe active thyroid eye disease. The results included achievement of both primary and secondary endpoints, increasing competitive pressure in the same treatment area where Viridian is also developing a therapy for thyroid eye disease.

Following the announcement, VRDN’s stock dropped approximately 19%, or $3.61, trading around $15.23 in morning activity. The move reflected investor concern that the new clinical data from a competing program could impact Viridian’s future commercial positioning and market expectations within the TED treatment landscape, particularly as both companies target overlapping patient populations and indications.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for serious rare diseases. It is primarily targeting thyroid eye disease with innovative biologic treatments designed to improve patient outcomes and reduce disease burden.

3. Byrna Technologies Inc. (NASDAQ:BYRN)

Price Target Upside: 175.23%

Byrna Technologies Inc. (NASDAQ:BYRN) is among the best 52-week low stocks to invest in.

TheFly reported on April 10 that Craig-Hallum downgraded BYRN from Buy to Hold and set a $7.50 price target, citing recent operational instability and leadership changes. The firm pointed to a new CEO appointment, along with a sharp decline in online conversion rates over the past two months, as key factors behind the weaker outlook. It noted that management is attempting to expand the customer base and rebuild marketing efforts, but expects these initiatives to require time and additional spending, which could weigh on profitability. Craig-Hallum also stated that current market expectations appear too high and suggested the shares may remain under pressure until consistent performance improvements justify a higher valuation.

Previously, on April 9, Byrna Technologies Inc. (NASDAQ:BYRN) reported fiscal first-quarter 2026 results showing net revenue of $29.0 million, up from $26.2 million in the prior-year period, reflecting continued expansion across dealer and retail chain channels. Gross profit rose to $17.4 million, although gross margin slightly declined due to a higher mix of dealer and chain store sales.

The corporation’s Operating expenses increased to $16.5 million, driven mainly by higher advertising, marketing, legal, and professional costs supporting distribution growth and brand awareness efforts. Net income was $0.8 million compared with $1.7 million a year earlier, while adjusted EBITDA totaled $2.2 million versus $3.0 million. The company also reported $9.6 million in cash and securities and noted ongoing efforts to improve working capital efficiency and reduce inventory levels over time.

Byrna Technologies Inc. (NASDAQ:BYRN) is a defense technology company that designs and manufactures non-lethal personal security products. Its portfolio includes CO2-powered launchers and projectiles intended for civilian, law enforcement, and security use as alternatives to firearms.

2. Forum Markets, Incorporated (NASDAQ:FRMM)

Price Target Upside: 179.33%

Forum Markets, Incorporated (NASDAQ:FRMM) is one of the best beaten-down stocks on this list.

TheFly reported on April 7 that Benchmark initiated coverage on FRMM with a Speculative Buy rating and a $5 price target. The firm highlighted the company’s strategic shift toward institutional-grade real-world asset tokenization built on Ethereum layer-2 networks, describing it as part of a broader transformation in global capital markets. It emphasized that Forum Markets has rapidly repositioned itself within this emerging segment and is aligned with expected expansion in tokenized asset adoption.

Separately, on April 8, Forum Markets, Incorporated (NASDAQ:FRMM) announced a new capital deployment initiative focused on providing short-term bridge loans for the acquisition and rollout of NVIDIA AI chips used in data center infrastructure. The arrangement involves financing hardware purchases before permanent funding becomes available, once projects become operational and revenue-generating. These loans are structured as short-duration instruments, typically repaid within 60 to 120 days through takeout financing from institutional lenders after deployment.

The business targets annualized returns in the mid-teens from its initial commitments and expects the strategy to enhance its broader tokenization platform. Forum also noted that it may tokenize portions of these investments, allowing AI infrastructure credit exposure to be distributed through its digital asset ecosystem. The initiative is designed to expand capital deployment opportunities while supporting rapidly growing demand for AI compute infrastructure.

Forum Markets, Incorporated (NASDAQ:FRMM) develops platforms that enable the conversion of illiquid, institutional-grade assets into blockchain-based financial instruments using Ethereum Layer 2 protocols.

1. BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

Price Target Upside: 1,076.47%

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is one of the best 52-week low stocks.

TheFly reported on April 2 that H.C. Wainwright lowered its price target on BTAI to $5 from $6 while maintaining a Buy rating. The firm attributed the revision to concerns over recent and expected equity dilution, which influenced its updated valuation outlook.

Separately, on April 8, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that it has begun enrolling the first patients in a U.S. Department of War-funded Phase 2a clinical study evaluating BXCL501 for acute stress reactions. The trial is being conducted in collaboration with the University of North Carolina at Chapel Hill Institute of Trauma Recovery and is designed as a randomized, placebo-controlled study enrolling around 100 participants who experience trauma-related acute stress, such as after motor vehicle accidents.

The research will assess whether BXCL501 can reduce symptom severity, improve cognitive functioning, and help prevent progression to longer-term neuropsychiatric conditions like post-traumatic stress disorder. The medication is being supplied by the company for the study. Acute stress reactions are common in both civilian and military populations and represent a large unmet medical need. The trial represents a key step in expanding clinical research for BXCL501 in trauma-related psychiatric indications and advancing potential pharmacological treatment options.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a clinical-stage biopharmaceutical company that uses artificial intelligence to identify and develop new therapies. It focuses on neuroscience and immuno-oncology, advancing treatments for conditions such as agitation, schizophrenia, and cancer.

READ NEXT: 10 Best Mid Cap Stocks to Invest In According to Billionaires and 10 Best Cheap Stocks Under $10 to Buy in April.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.